A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

To join this study, you would need to have a confirmed diagnosis of low-grade serous ovarian cancer. Your cancer must have returned or progressed after you've already had at least one other treatment for it that spread to other parts of the body. Also, doctors need to be able to measure your cancer on scans.\n\nThere are other health checks too. You need to be generally well enough to take part, with important body functions (like your liver and kidneys) working properly. Any side effects from your previous treatments should have mostly cleared up. If you are able to become pregnant, you would need to agree to use effective contraception during the study.\n\nYou can't join if you've had certain treatments very recently, like other anti-cancer drugs or major surgery. You also can't have other types of ovarian cancer alongside the low-grade serous type. If you have serious heart or lung problems, or conditions like active skin issues or a history of specific muscle problems, you might not be able to participate. Also, recent severe COVID-19 symptoms or brain metastases requiring medication would prevent you from joining.

If you decide to take part in this study, you will likely have regular visits to the clinic for assessments. These visits will involve physical examinations, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. You will be taking the study medication by mouth, as advised by the study team. Some participants will receive avutometinib on its own, while others will receive avutometinib plus defactinib. The total duration of your participation will depend on how you respond to the treatment and your overall health, but there will be ongoing follow-up to check on your progress and well-being.